Arvinas (NASDAQ:ARVN) was given a new $18.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating [Yahoo! Finance]
Arvinas (NASDAQ:ARVN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]